Krajina: Kanada
Jazyk: angličtina
Zdroj: Health Canada
ENOXAPARIN SODIUM
JUNO PHARMACEUTICALS CORP.
B01AB05
ENOXAPARIN
150MG
SOLUTION
ENOXAPARIN SODIUM 150MG
INTRAVENOUS
15G/50G
Prescription
HEPARINS
Active ingredient group (AIG) number: 0131860002; AHFS:
APPROVED
2020-10-14
_ _ _NOROMBY _ _Page 1 of 78_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr NOROMBY TM Enoxaparin sodium Solution for injection, 100 mg/mL BP 20 mg/0.2 mL 30 mg/0.3 mL 40 mg/0.4 mL 60 mg/0.6 mL 80 mg/0.8 mL 100 mg/mL (Subcutaneous or Intravenous Use Only) Pr NOROMBY TM HP Enoxaparin sodium Solution for injection, 150 mg/mL BP 120 mg/0.8 mL 150 mg/mL (Subcutaneous or Intravenous Use Only) ATC Code: B01AB05 Anticoagulant/Antithrombotic Agent Juno Pharmaceuticals Corp. 402-2233 Argentia Road Mississauga, Ontario L5N 2X7 Date of Initial Approval: October 14, 2020 Date of Revision: February 12, 2021 Submission Control No: 233058 _ _ _NOROMBY _ _Page 2 of 78_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...............................................................4 1 INDICATIONS ..............................................................................................................4 1.1 Pediatrics ............................................................................................................4 1.2 Geriatrics ............................................................................................................4 2 CONTRAINDICATIONS................................................................................................4 3 DOSAGE AND ADMINISTRATION...............................................................................5 3.1 Dosing Considerations.........................................................................................5 3.2 Recommended Dose and Dosage Adjustment .....................................................5 3.3 Administration .....................................................................................................8 3.4 Missed Dose .....................................................................................................10 4 OVERDOSAGE ..........................................................................................................10 5 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING................ Prečítajte si celý dokument